Doctors Revision

CNS Stimulants: Pharmacology, Clinical Use, Dosing and Safety

Text size
On this page

1. Overview

Central nervous system (CNS) stimulants increase alertness, attention or wakefulness by enhancing catecholamine signalling. They include essential prescription medicines — methylphenidate, amphetamine-class drugs and modafinil — used for ADHD and narcolepsy, and widely consumed substances such as caffeine. Because they are controlled medicines with misuse potential, correct indication, formulation choice and safety monitoring are as important as the pharmacology itself.

Learning outcomes: classify the stimulants; compare mechanisms of action; state adult and paediatric dosing with key cautions; recognise toxicity; and counsel on dependence, diversion and sleep hygiene.

2. Classification and mechanisms

Scroll the table sideways on a smaller screen.

Classification of CNS stimulants
ClassExamplesCore pharmacology
Amphetamine-typeLisdexamfetamine, dexamfetamineEnter the presynaptic neuron, reverse dopamine/noradrenaline transporters and block reuptake → net catecholamine release
Methylphenidate-typeMethylphenidate (IR and MR)Blocks dopamine and noradrenaline reuptake transporters (DAT, NET) → ↑synaptic catecholamines, especially in prefrontal cortex
Wakefulness-promotingModafinil, armodafinilMechanism incompletely defined; acts through dopamine transporter inhibition and orexin/histamine systems
MethylxanthinesCaffeine, theophyllineAdenosine-receptor antagonism; higher doses inhibit phosphodiesterase and mobilise Ca²⁺
Historical/misuse stimulantsCocaine, ephedrineCocaine blocks monoamine reuptake (also local anaesthetic); toxicology teaching, not therapy

Exam distinction: methylphenidate blocks reuptake whereas amphetamines actively release and reverse transporters. Both raise prefrontal dopamine and noradrenaline, improving attention and impulse control in ADHD. In a person without ADHD, the same drugs do not improve learning — they increase anxiety, insomnia, blood pressure and dependence risk.

3. Clinical uses

  • ADHD (≥6 years): first-line pharmacotherapy alongside psychoeducation, parent/teacher training and school support; drug treatment alone is not management.
  • Narcolepsy: modafinil first-line; stimulants or sodium oxybate alternatives per specialist protocol.
  • Apnoea of prematurity: caffeine citrate in neonatal units (loading 20 mg/kg, then 5 mg/kg/day maintenance) — specialist neonatal dosing, never extrapolated to older children.
  • Exogenous (non-medical) use: performance-seeking, weight loss, euphoria — the principal source of harm and of the controlled-drug framework.

4. Drugs in detail

4.1 Methylphenidate

Scroll the table sideways on a smaller screen.

Methylphenidate
AspectDetail
Adult dosingIR: start 5–10 mg BD–TDS (2–3 doses/day), titrate weekly; typical total 20–30 mg/day, max 60 mg/day. MR formulations once daily, morning.
Paediatric dosing (ADHD, ≥6 y)IR: 5 mg BD–TDS → up to 60 mg/day; MR: start 10–20 mg OD → max 60 mg/day (product-dependent). Stop and reassess after drug holidays.
IndicationsADHD (first-line); narcolepsy.
Adverse effectsReduced appetite and weight loss, insomnia, headache, abdominal pain, tachycardia, raised BP, irritability; rare growth suppression (monitor height/weight), tics, psychosis.
ContraindicationsSerious cardiac disease or arrhythmia, glaucoma, severe anxiety, current/recent MAOI use, uncontrolled hypertension, misuse of sympathomimetics.
InteractionsMAOIs — hypertensive crisis (never combine); pressor agents, TCAs, SSRIs (↑levels/SI risk); anticonvulsants (phenytoin, phenobarbital lower levels); caffeine adds side effects.
CounsellingMorning dosing (IR last dose before ~6 pm) to protect sleep; take after food; do not share/sell; rinse mouth; report chest pain, fainting or mood change; store securely — controlled drug.

4.2 Lisdexamfetamine and dexamfetamine

Scroll the table sideways on a smaller screen.

Amphetamine-class stimulants
AspectLisdexamfetamineDexamfetamine
DosingADHD ≥6 y and adults: 30 mg once each morning → increase in 10–20 mg steps weekly; max 70 mg/day.IR: 2.5–5 mg BD → titrate; divided doses; product/indication-dependent max.
PharmacokineticsProdrug — converted to dextroamphetamine in RBCs; smoother, longer effect, lower peak ("abuse-deterrent").Direct amphetamine; faster onset, shorter duration, higher misuse potential.
Adverse effectsAppetite suppression, weight loss, insomnia, dry mouth, tachycardia/hypertension, anxiety, agitation; Raynaud-type vasculopathy; psychosis/mania at high exposure.
Contraindications / interactionsAs methylphenidate — MAOIs absolutely contraindicated; caution with antihypertensives, acidic urine alkalinisers alter excretion; serotonergic drugs risk serotonin syndrome.
CounsellingNever crush/chew (lisdexamfetamine only); take on waking; expect appetite suppression — plan meals; report unexplained fainting, chest pain, aggressive outbursts.

4.3 Modafinil

Scroll the table sideways on a smaller screen.

Modafinil
AspectDetail
DosingNarcolepsy adults: 200 mg once each morning; some divide 100 mg morning + noon. Hepatic impairment: halve dose. Not licensed for children in many regions.
Adverse effectsHeadache, nausea, nervousness, insomnia, anxiety; serious rash including Stevens–Johnson syndrome (stop at first sign of rash); psychiatric symptoms in predisposed patients.
InteractionsInduces CYP3A4 → reduces hormonal contraceptive efficacy — advise alternative/barrier method during treatment and for 2 months after stopping; inhibits CYP2C19 (raises e.g. some antidepressant levels); lowers cyclosporine levels.
CounsellingReport any rash immediately; headaches often settle; avoid evening dosing; contraceptive counselling for women of childbearing age.

4.4 Caffeine and the methylxanthines

Scroll the table sideways on a smaller screen.

Approximate caffeine content of common sources
SourceApprox. caffeineComment
Instant/filter coffee (1 cup)60–120 mgTotal daily intake matters — count every source including "energy" drinks, cola, tea and combination analgesics; safe general limit ≈400 mg/day in healthy adults
Black tea (1 cup)30–50 mg
Energy drink (250 mL)80 mg
Cola (330 mL)30–40 mg
  • Effects at modest intake: alertness, mild bronchodilation, diuresis; high intake: tremor, anxiety, insomnia, tachycardia, arrhythmia, hyperglycaemia.
  • Withdrawal: headache, fatigue, irritability — treat by gradual taper.
  • Drug interactions: additive with stimulants; reduces lithium clearance (raises levels); theophylline and ciprofloxacin raise caffeine levels.
  • Pregnancy: limit to <200 mg/day; higher intakes linked to low birth weight and miscarriage.

4.5 Worked example — starting a child on methylphenidate

  1. Confirm the diagnosis: 8-year-old with teacher- and parent-reported inattention, impulsivity and poor task completion across two settings for >6 months; no alternative explanation (sleep apnoea, anaemia, thyroid, anxiety, epilepsy).
  2. Baseline: weight 27 kg (25th centile), height 125 cm, BP 100/64, pulse 92; no cardiac history; family history negative for sudden death; good sleep; no tics; normal mood; no substance use.
  3. Start: methylphenidate IR 5 mg each morning on school days; give after breakfast; agree functional target ("completes classwork without leaving seat").
  4. Review at 1 week: appetite reduced but eating after school; sleep intact; pulse 96, BP 102/66; teacher reports improved task completion → add 5 mg at midday.
  5. Review at 1 month: weight 26.5 kg (—0.5 kg) — monitor; plan calorie-dense evening meal; consider drug holidays over long school breaks; if weight loss >1 kg or growth-line crossing, switch formulation or reduce dose.
  6. Safety script for parents: store locked (controlled drug), never share or sell, report chest pain/fainting/mood change immediately, keep school informed, review every 3–6 months with height, weight, BP and pulse charted.

4.6 Worked example — stimulant misuse in the emergency department

A 20-year-old student presents 3 hours after ingesting a "handful" of a friend's lisdexamfetamine with energy drinks: agitated, HR 128, BP 178/104, T 38.9 °C, sweaty, pupils dilated. Management: ABCDE; glucose and ECG (sinus tachycardia); benzodiazepine for agitation per protocol; active cooling for hyperthermia; treat complications (severe hypertension, arrhythmias, rhabdomyolysis — check CK and renal function, urine output); avoid beta-blockade alone (unopposed α-adrenergic effect); admit for observation; involve psychiatry and discuss dependence. The key counselling point afterwards: stimulants taken without a diagnosis help performance far less than students believe and add real cardiovascular and psychiatric risk.

5. Baseline assessment and monitoring

  • Diagnosis and goals: confirmed ADHD diagnosis, functional impairment, measurable target (e.g., school performance, task completion).
  • Vitals: pulse, BP, weight/height (children), cardiovascular history, family history of sudden death <40 years.
  • Psychiatric screen: anxiety, depression, mania/bipolar, psychosis, tics, sleep pattern, suicidal ideation.
  • Misuse and safeguarding: substance-use history, diversion risk, coercion, count tablets if concern.
  • Review at every dose change: pulse, BP, weight, sleep, appetite, psychiatric symptoms, growth chart in children; ECG if cardiac risk factors or abnormal examination.

6. Adverse effects, interactions and toxicity

Interaction clusters to memorise: (1) MAOIs + any stimulant = hypertensive crisis/serotonin syndrome; (2) sympathomimetic decongestants (pseudoephedrine) and appetite suppressants add cardiovascular load; (3) CYP inhibitors/ inducers move methylphenidate, amphetamine and modafinil levels; (4) serotonergic combinations risk serotonin syndrome.

7. Dependence, diversion and counselling

  • Never share, sell, crush, snort or inject tablets; controlled-drug storage and records.
  • Lowest effective dose, regular review — treatment is not "set and forget".
  • Morning/early-day dosing; avoid stacking caffeine; check before using cold remedies or supplements.
  • Urgent care for chest pain, fainting, severe headache, hallucinations, suicidal thoughts, suspected overdose.
  • Sleep hygiene: consistent schedule, no screens late, no late dosing; insomnia on stimulants usually means dose too late or too high.
  • School liaison: teachers should confirm the functional benefit — this is your titration endpoint.

8. Exam points

  • Mechanism contrast: reuptake blockade (methylphenidate) vs transporter reversal/release (amphetamines) vs undefined (modafinil) vs adenosine antagonism (caffeine).
  • Maxima: methylphenidate 60 mg/day; lisdexamfetamine 70 mg/day; modafinil 200 mg/day (hepatic: 100 mg).
  • Three "never-forget" cautions: MAOI contraindication, modafinil–contraceptive interaction, growth monitoring in children.
  • OSCE counselling structure: indication/formulation → vitals → sleep/mood/substances → interactions → functional target → timing, storage, red flags → review plan.

References

  • NICE guideline NG87 — Attention deficit hyperactivity disorder: diagnosis and management. (Library reference.)
  • Product labels / DailyMed — methylphenidate, lisdexamfetamine, modafinil prescribing information. (Library reference.)
  • Katzung's Basic & Clinical Pharmacology, CNS stimulant chapter. (Library reference.)
  • SlideShare teaching collections — "CNS stimulants and cognitive enhancers". (Library reference.)

For education only. Apply current Uganda Clinical Guidelines, local protocols and specialist advice in clinical practice.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top